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Airway epithelial cells are the ﬁrst line of defense against invading microbes, and they protect themselves through the production
of carbohydrate and protein matrices concentrated with antimicrobial products. In addition, they act as sentinels, expressing
pattern recognition receptors that become activated upon sensing bacterial products and stimulate downstream recruitment and
activation of immune cells which clear invading microbes. Bacterial pathogens that successfully colonize the lungs must resist
these mechanisms or inhibit their production, penetrate the epithelial barrier, and be prepared to resist a barrage of inﬂammation.
Despite the enormous task at hand, relatively few virulence factors coordinate the battle with the epithelium while simultaneously
providing resistance to inﬂammatory cells and causing injury to the lung. Here we review mechanisms whereby airway epithelial
cells recognize pathogens and activate a program of antibacterial pathways to prevent colonization of the lung, along with a few
examples of how bacteria disrupt these responses to cause pneumonia.
1.Introduction
Host defense in the mammalian lung relies heavily on innate
immune mechanisms that prevent invasion of pathogens.
The airway epithelium is the front line defender of the lung
which signals recruitment and activation of eﬀector cells
to kill invading pathogens and provides a physical barrier
loaded with antibacterial compounds. Bacteria that success-
fully penetrate the epithelium must have the capability to
evade these mechanisms, which typically means they avoid
recognition and killing by both the eﬀector cells of the
innate immune system and the antimicrobial mechanisms
in the epithelium. Pneumonia is a consequence of lung
colonization, pathogen-induced injury to the epithelium,
sustained activation of inﬂammation, and overactivation
of tissue repair mechanisms. Furthermore, vascular leakage
and edema are caused by these host responses, allowing
the pathogen to gain access to the blood, where it may
spread systemically and cause sepsis. Bronchopneumonia is
characterized by focal areas of congestion of the parenchyma
by bacteria, inﬂammatory cells, and ﬁbrin while lobar
pneumoniaisdeﬁnedbyasingleareaofcongestionthattakes
up a larger portion of a lung lobe. Interstitial pneumonia
involves congestion in the surrounding vasculature and is
typicallytheresultofoveractiverecruitmentofinﬂammatory
cells. In this paper, we will discuss how airway epithelial cells
orchestrate innate immune responses in the lungs in order to
limit invasion of bacterial pathogens, mediate tissue repair,
and prevent pneumonia.
The airway epithelium can be subdivided into bronchial
and alveolar epithelial cells, which are polarized cells that
share function in providing both a physical barrier and
antimicrobial activity. The bronchial epithelial and goblet
cells line the large airways, and these cells regulate ion
exchange, mucin production, inﬂammation, and repair
responses [1]. These cells form a physical barrier, connected
by tight junctions, adherens junctions, and desmosomes
that are relatively impermeable [2]. Similarly, the alveolar
epithelium, composed of two distinct cell types, produces2 Journal of Pathogens
antibacterial compounds such as surfactant, initiates and
terminates inﬂammation, and regulates gas exchange to
provide oxygen to the body. Resident alveolar macrophages
and occasionally dendritic cells are also found in the alveolar
epithelium and are key mediators of innate and adaptive
immunity. Type I alveolar epithelial cells function primarily
in facilitating gas exchange, but they also comprise a large
portion of the impermeable barrier and can sense and
respond to microbial products. Type II alveolar epithelial
cells, also called type II pneumocytes, function as defenders
of the airway through secreting antimicrobial products,
sensing pathogenic invasion, and producing cytokines and
chemokines that both activate and deactivate inﬂammation.
In addition, type II cells can diﬀerentiate into type I cells and
secrete repair enzymes upon damage to the epithelium.
Mucins are continuously secreted by intraepithelial gob-
let cells and are composed of large glycoproteins that cross-
link to form a structural barrier [1]. This property causes
small and large particles, such as proteins and whole cells, to
become trapped. Mucus contains a variety of antimicrobial
compounds including IgA, collectins, and defensins which
are regulated by the transcription factors NF-κBa n dS p -
1[ 2]. Microbes and other particulate material are pumped
outward through the action of the mucociliated bronchial
epithelium, a process that requires calcium transport, and
serves as an environment for the activity of antimicrobial
compounds [3]. Activation of NF-κB following signaling
fromthesentineltoll-likereceptors(TLRs)inducesepithelial
cells to increase production of these compounds as well
as proinﬂammatory cytokines which in turn also induce
increased production of mucin. Together, these processes
result in concentrated antimicrobial products that are
broadly eﬀective against invading microbes.
Type II pneumocytes secrete surfactants on the apical
side of the cell which are fatty acids that elicit similar
functions as mucins. Four surfactant-associated proteins,
SpA-D, are also produced by type II cells that function to
agglutinate microbes to facilitate their clearance. Surfactant
protein B has antimicrobial activity against bacteria by
enhancing the phagocytic function of alveolar macrophages
[4]. A number of antimicrobial products including β-
defensins, lipocalin, and nitric oxide, as well as complement
protein C3 and interferon are secreted into the surfactant
layer (Table 1). Lipocalin chelates Fe+3, limiting the access
of bacteria to essential iron thereby stunting microbial
growth [5]. β-defensins and nitric oxide provide direct
killing of bacteria. β-defensins are small cationic antimi-
crobial peptides (CAMPs) with bactericidal activity and are
attracted to the negative charge of the bacterial membrane.
To maintain adequate concentrations of these peptides in
the surfactant layer they are continuously secreted [6].
Type II epithelial cells also secrete repair enzymes, such as
ﬁbrinogen, on the basolateral face [7]. They quickly respond
to changes in osmotic stress thereby able to sense nanomolar
concentrations of bacterial pore-forming toxins. This allows
cells to activate an inﬂammatory response long before the
toxin is lethal to the cell [8].
Resident alveolar macrophages are phagocytic cells with
distinct properties and initiate recruitment of inﬂammatory
cells, such as neutrophils, as well as present antigen to cells
of the adaptive immune system [9]. Uptake of pathogens by
alveolar macrophages can be stimulated through antibody
or complement opsonization, both of which are produced
by airway epithelial cells and are also present in the blood.
Recognition of intracellular or extracellular bacteria by
pattern recognition receptors (PRRs) expressed by alveolar
epithelial cells and macrophages stimulates an increase in
the production of antimicrobial compounds, complement,
cytokines, and chemokines which recruit eﬀector cells such
as neutrophils, monocytes, and dendritic cells, as well as
T and B cells (Table 1)[ 10]. Inﬂammatory monocytes and
neutrophils, however, must not reside in the lung long
term because they produce and secrete cytotoxic molecules
that will injure the delicate type I cells. Instead, polarized
secretion of cytokines and chemokines by type I and II
cells promotes recruitment, adherence, and transepithelial
migration of inﬂammatory cells to ﬁght infection, which
is subsequently downregulated to limit their damage to the
epithelium [11].
Bacterial pathogens penetrate the epithelium either
through its disruption or by directly invading the airway
epithelial cells. Disruption can be achieved by the induction
of apoptosis or the use of bacterial exotoxins that directly
lyse cells [12]. The use of toxins to promote penetration
of epithelial barriers triggers injury responses that activate
inﬂammation independent of pathogen recognition. In
many cases, pathogens delay or prevent repair of the epithe-
lium and these injury responses exacerbate lung congestion
and accelerate disease [13]. In addition, some opportunistic
pathogens derive help in crossing the epithelium through
coinfection with viruses that impair mucociliary function,
thereby allowing disruption of the epithelial barrier.
Many bacterial pathogens have obligate or faculta-
tive intracellular life cycles enabling them to invade the
epithelium, survive, and replicate in multiple environments.
Bronchial and alveolar epithelial cells are not naturally
phagocytic. Rather, some bacteria carry virulence factors
that promote their entry into these cells. Once inside the
epithelial cells, pathogens encode mechanisms that subvert
normal traﬃcking pathways such that they may replicate
in a membrane bound compartment or the cytoplasm. In
order to replicate extracellularly, organisms must escape the
cell which typically involves lysis caused by bacterial pore-
forming toxins, induction of apoptosis, or may simply be the
result of massive replication.
2. Pathogen Detection
Detection of conserved structural motifs, termed pathogen
associated molecular patterns (PAMPs), is achieved by the
expression of surface receptors, both on the cell surface and
in endosomes. Detection ofaninvading bacteriumthrough a
particular PRR results in the production of proinﬂammatory
cytokines and chemokines that recruit and activate immune
eﬀector cells, such as granulocytes and T cells, to the site of
infection. In addition to mediating a localized inﬂammatoryJournal of Pathogens 3
Table 1: Immunomodulatory roles of type II alveolar epithelial cells.
Role Component Function Ref
Antimicrobial
Complement Membrane disruption, opsonization, and inﬂammation [6]
Cathelicidin Membrane disruption [6]
β-defensins Membrane disruption [6]
Immunoglobulin Complement-mediated lysis, agglutination, and opsonization [6]
Lipocalin 2 Iron sequestration [6]
Lysozyme Membrane disruption [6]
Nitric oxide Membrane disruption [5]
Surfactant Agglutination (SpA, SpD), membrane disruption (SpB) [6]
Inﬂammation
TLR2 Recognition of lipoproteins, lipoteichoic acid, and peptidoglycan [6]
Receptors
TLR4 Recognition of lipopolysaccharide [6]
IL-2R IL-2 receptor [5]
TNF-R1 TNFα receptor [5]
MHC-I Antigen presentation to CD8 T cells [6]
MHC-II Antigen presentation to CD4 T cells [6]
Cytokines and
chemokines
IL-1α Prostaglandin production, induces TNFα [6]
IL-1β Prostaglandin production, induces TNFα [6]
IL-4 Th2 Polarization, immunoglobulin production [5]
IL-6 T cell recruitment, B cell diﬀerentiation [6]
IL-8 Neutrophil chemotaxis [6]
GRO-α Neutrophil chemotaxis [6]
ENA-78 Neutrophil chemotaxis [6]
MIP-2 Neutrophil chemotaxis [6]
TNF-α Vasodilation, neutrophil activation [6]
GM-CSF Granulocyte and monocyte diﬀerentiation [5]
RANTES Monocyte and T cell recruitment [6]
MCP-1 Monocyte and T cell recruitment [6]
IFN-α/β MHC-I Expression, NK cell activation [6]
IFN-γ Th1 Polarization, macrophage activation [5]
response, soluble PRRs and antimicrobial peptides can
also directly mediate killing of invading organisms through
disruption of the cell membrane, resulting in osmotic lysis of
bacteria [14].
Toll-like receptors (TLR) are transmembrane proteins
that form a major family of PRRs and are ubiquitously
expressed. TLRs form homo- and heterodimers with other
TLRs or accessory proteins that are together responsible
for the recognition of a variety of PAMPs including bac-
terial lipoprotein, lipopolysaccharide (LPS), peptidoglycan,
ﬂagellin, RNA, and nonmethylated CpG DNA. Diﬀerent
complexes are thought to mediate speciﬁc signal trans-
duction pathways allowing for an increased repertoire of
downstream responses. These proteins signal both innate,
and adaptive immune responses and their collective action
is essential for immune defense against bacterial pathogens.
TLR2, 4, and 5 detect most species of bacteria and each of
these signal through the common adaptor protein MyD88,
located on the cytoplasmic face of the plasma membrane.
Signal transduction via phosphorylation cascade activates
the nuclear translocation of NF-κB, which leads to the
production of proinﬂammatory cytokines and chemokines.
In addition, MyD88-independent signaling can also occur,
leading to the expression of type I interferons (IFN-I) which
also activate expression of proinﬂammatory cytokines and
chemokines [15].
BacterialLPSiscomposedoflipidA,corepolysaccharide,
and O-antigen. Lipid A composition varies between bacterial
species and between cells of the same species and plays an
important role in the pathogen’s ability to colonize the host
lung. Recognition of lipid A is achieved by the delivery of
monomeric LPS micelles to CD14 by soluble LPS-binding
protein (LBP) [16]. TLR4, in complex with the accessory
protein MD2, then associates with CD14 forming the TLR4-
MD2-CD14 LPS receptor complex. Upon complex forma-
tion, the cytoplasmic tail of TLR4 is able to associate with
MyD88 leading to NF-κB activation. Alternatively, TLR4
can also signal through the adaptor TRIF/TRAM leading4 Journal of Pathogens
to the activation of the transcription factor IRF-3 and the
subsequent expression of type I interferon [17, 18]. Both the
MyD88-dependentandindependentpathwaysareimportant
for host defense in the lungs, as mice deﬁcient in these pro-
cesses are more susceptible to pulmonary infection by many,
but not all, bacterial species. Moreover, each pathway plays
a distinct role against speciﬁc pathogens. TLR4 signaling
can be initiated either on the cell surface or from the cyto-
plasm where the receptor remains associated with pathogen
containing endosomes. In addition, TLR4 signaling induces
crosstalk with other PRRs. For example, TLR4 activation
upregulates surface expression of TLR2, enhancing the
capacity of cells to be activated in response to PAMPs [19].
TLR2 primarily responds to Gram-positive bacteria
through the detection of lipoteichoic acid and peptido-
glycan from the apical surface of airway epithelial cells
[20]. TLR2 has several coreceptors, including CD14 and
CD36, which likely lead to speciﬁc activation patterns. In
addition, gangliosides, some of which function as receptors
for pathogen invasion, can also act as coreceptors for TLR2
and alter its ability to respond to PAMPs. Like TLR4,
TLR2 signaling can be MyD88-dependent or independent,
resulting in NF-κB or IRF-3 activation and can be activated
from the cell surface or from intracellular compartments
[21]. In addition to the toll-like receptors, other PRRs
such as the nucleotide oligomerization domain (NOD)-like
receptors (NLRs), sense intracellular pathogens through the
detectionofpeptidoglycanandbacterialDNAinthehostcell
cytoplasm.Retinoid-induciblegeneI(RIG-I)andmelanoma
diﬀerentiation-associated gene 5 (MDA5) are RNA helicases
that recognize microbial RNA and methylated DNA in
the cytoplasm and activate IRF-3 [22]. In addition, DNA
activator of interferon regulatory factors (DAI) is a major
cytosolic DNA sensor that also leads to the activation of
IRF-3 [23–25]. Thus, bacterial DNA is a potent inducer of
inﬂammation through its eﬀect on IFN-I gene expression
f r o me p i t h e l i a lc e l l sa sw e l la sa l v e o l a rm a c r o p h a g e s .
TLR2, 4, and 5 are the primary sensors of bacteria,
and crosstalk occurs between other toll-like receptors that
respond to viral infection. For example, viral activation of
TLR3 not only stimulates production of proinﬂammatory
cytokines in type II cells but also leads to upregulation of
TLR2 and some, but not all, of its coreceptors allowing for
enhanced detection of bacteria [26]. In contrast, TLR5 is
downregulatedfollowingTLR3activationtherebydecreasing
the ability to respond to bacterial ﬂagellin, leaving an
opportunity for bacterial coinfection.
In addition to impacting PAMP recognition, viral infec-
tion may also assist in the deterioration of the airway
epithelium or in modulating immune responses, leading to
increased susceptibility to secondary bacterial pneumonia
caused by opportunistic pathogens [27]. Many viruses
destroy mucus producing or ciliated cells. Alternatively, viral
infectionmayactivatecelldeathpathwaysthattheninﬂuence
the ability of epithelial cells to respond to secondary
infection. For example, following inﬂuenza virus infection,
the host recruits monocytes to the airways which contribute
proapoptotic signals to type I epithelial cells [28]. The
resulting decay of the alveolar barrier can be exploited by
opportunistic pathogens now able to invade and grow within
the air spaces. Furthermore, inﬂuenza infection also depletes
the host of eﬀector cells such as monocytes, macrophages,
and natural killer (NK) cells [28, 29].
3. Pathogen Clearance and
Resolution of Inﬂammation
Cytokines and chemokines produced by airway epithelial
cells rapidly stimulate recruitment and activation of neu-
trophils, eosinophils, monocytes, dendritic cells (DCs), and
NK cells which are capable of destroying invading bacteria
[30–33]. By 6 or 7 days postinfection, T cells are also
recruited by RANTES or IP-10 production (for Th1 cells)
andIL-1β(forTh2cells).Subsequently,airwayepithelialcells
receive signals from recruited inﬂammatory cells to increase
production of defense mechanisms. For example, elastase
is a bactericidal serine protease stored in granuoles and is
secreted by activated neutrophils in response to infection
[34]. Following release of the granules, bronchial epithelial
cells respond to elastase by upregulating the expression of β-
defensins [35].
Because inﬂammatory cell activity in the airway is likely
to cause tissue damage and congestion that interferes with
lung function, epithelial cells also mediate downregulation
of inﬂammatory responses following bacterial clearance in
order to protect the lung from unnecessary tissue damage.
Production of glucocorticoids and other lipids, as well as
anti-inﬂammatory cytokines, such as IL-10 and TGF-β,b y
airway epithelial cells help to downregulate inﬂammation
[36]. Lysophosphatidic acid (LPA) is a mediator produced
by epithelial cells that regulates expression of pro- and anti-
inﬂammatory cytokines and chemokines. This phospholipid
acts by blocking the binding of interferon response factor-
1 (IRF-1) to DNA, thereby reducing its ability to stimulate
expression of downstream proinﬂammatory genes. LPA can
also induce expression of lipid mediators of inﬂammation
as well as repair enzymes. Costimulatory signals inﬂuence
downstream responses, for example, IFN-γ and TNF-α co-
stimulation of bronchial epithelial cells results in LPA-
mediated downregulation of the neutrophil chemokine
CCL5/RANTES. As IFN-γ and TNF-α are induced by
pathogens and accumulate in the bronchus, LPA production
by epithelial cells prevents long-term recruitment of neu-
trophils to prevent unnecessary damage to the lung.
4. BacterialPneumonia
When these defense mechanisms fail to prevent bacterial
infection, pneumonia rapidly develops. Bacterial pneumonia
can be subdivided into community acquired and hospital
acquired. The most common community and hospital
acquired pneumonia is caused by Streptococcus pneumoniae,
an extracellular, opportunistic pathogen whose virulence is
primarily derived from the production of a capsule which
allows the organism to adhere to mucosal tissues and
evade the innate immune responses of the lung, including
surfactants, complement, and phagocytosis [37]. Others,Journal of Pathogens 5
such as Klebsiella pneumoniae and Acinetobacter baumannii,
primarily cause hospital acquired infections using similar
strategies [38, 39]. In contrast, community acquired pneu-
monia can be caused by other pathogens that target the
lung as a primary replicative niche using multiple virulence
strategies. For example, Francisella tularensis, Staphylococcus
aureus,a n dYersinia pestis cause lung injury as extracellular
pathogens through the production of secreted toxins, but
employ an intracellular life cycle that relies on entirely
diﬀerent virulence mechanisms to invade the epithelium,
evade innate immune detection, and establish a successful
infection. These pathogens have in common the capacity
t op r o d u c en u m e r o u sm o d u l a t o r so fd e t e c t i o n ,a sw e l la s
virulence factors that serve multiple roles during infection.
However, the mechanisms whereby these pathogens evade
the onslaught of detection and destruction initiated by
airway epithelial cells are very diﬀerent. Because of their
abilities to disable multiple levels of innate immunity in the
lungs, we will discuss these three pathogens in greater detail.
4.1. Francisella tularensis. Francisella tularensis infection
through tick transmission, wound infection, or inhala-
tion results in a number of disease manifestations in
humans such as oculoglandular, oropharyngeal, gastroin-
testinal, typhoidal, and pneumonic tularemia [40]. Several
subspecies have been identiﬁed and have varying degrees
of pathogenicity, with F. tularensis subsp. tularensis (type
A strain) being the most lethal, and F. tularensis subsp.
holarctica (type B strain) being less pathogenic. F. tularensis
subsp. holarctica is the parent strain of the attenuated Live
Vaccine Strain (LVS) which was established by serial passage
in the laboratory and was used as a vaccine for many years.
A third subspecies, F. tularensis subsp. novicida, rarely causes
disease in humans but is highly virulent in mice and is also
routinely used as a model system for F. tularensis research
[41]. Important mechanisms of virulence and immunity
have been elucidated in the attenuated Francisella strains,
yet signiﬁcant diﬀerences exist in the ability of the human
pathogens to control inﬂammatory responses and cause
disease.
Pneumonic disease develops as a sequela of systemic
infection, or as a result of inhaling bacteria and is charac-
terized as a lobar pneumonia [40]. Symptoms are typically
nonspeciﬁc and include fever, headache, and muscle aches,
but patients can also present more severe indicators such
as chest pain, bloody sputum, and dyspnea [42]. If left
untreated, mortality rates reach 30–60%. Francisella is a
facultative intracellular pathogen that targets macrophages
and epithelial cells, and this interaction is essential for
virulence. Bacteria interact with a multitude of receptors and
aretakenupbyalveolarmacrophagesfollowingopsonization
in a process termed “looping phagocytosis” [43–45]. Nascent
Francisella containing phagosomes do not mature into
phagolysosomes but instead are lysed, allowing the bacteria
to escape to the cytoplasm and replicate [46–48]. Escape
from the phagosome and intracellular replication is depen-
dent on the Francisella pathogenicity island (FPI) which
encodes a Type VI secretion system [49, 50]. Expression of
FPI genes is dependent on the global virulence regulator
MglA [51]. Organisms eventually reside in autophagous
vacuoles termed Francisella containing vacuoles (FCV) [48].
High level intracellular replication is thought to ultimately
lead to macrophage lysis and spread of extracellular bacteria
[52].
The presence of IFN-γ signiﬁcantly increases the resis-
tance of mice to Francisella infection [53, 54]. IFN-γ sig-
naling through the IFN-γ receptor stimulates macrophages
to upregulate bactericidal eﬀector function against all three
Francisella strains [55]. In murine and human macrophages,
IFN-γ inhibitstheintracellulargrowthofF. novicida andLVS
in an iNOS-independent (inducible nitric oxide synthase)
manner, likely by preventing bacteria from escaping the
phagosome thereby promoting lysosomal fusion [56–58]. In
contrast, F. tularensis phagosomal escape is not inhibited by
IFN-γ,andgrowthisinsteadrestrictedinthecytoplasm[59].
The outer membrane protein OmpC of F. novicida inhibits
IFN-γ inducedSTAT1phosphorylationinmacrophages[60].
Although OmpC is conserved in the other Francisella spp.,
further studies are needed to determine if OmpC also blunts
IFN-γ signaling for the human pathogens.
Similar to other Gram-negative bacteria, Francisella has
an LPS structure that contains lipid A, core, and O-antigen
domains that are important to the pathogenesis of the
organism [16, 61]. Francisella lipid A does not elicit an
inﬂammatory response through TLR4 due to a lack of LBP
binding [62–65]. Structural comparisons of Francisella lipid
A to those that are highly proinﬂammatory, such as found
in E. coli, indicate that its dephosphorylated glucosamine
backbone and tetra-acylation may not be recognized by
LBP, thereby preventing TLR4 signaling [66–70]. Artiﬁcial
stimulation of TLR4 pathways before and after F. novicida
infection,oruseofastrainalteredinlipidAstructure(ﬂmF2,
ﬂmK,a n dlpxF) induces an inﬂammatory response that
lowers bacterial burden in the lung and increases the survival
ofinfectedmice,illustratingtheimportanceofavoidingLPS-
dependent TLR4 activation for pathogenesis [70–72].
Inaddition,intactFrancisella LPSc or ehasbeensho wnto
beimportantinregulatingcytotoxicitytowardsmacrophages
[73]. When core components are mutated, the bacte-
ria are attenuated and hypercytotoxicity towards J774.A1
macrophages is observed and that results in attenuated
virulence. Interestingly, core mutants are able to invade
macrophages treated with cytochalasin-D, indicating that
uptake can be independent of phagocytosis and suggesting
the existence of a surface located receptor. Moreover, the
enhanced cytotoxicity of core mutants is caused by intracel-
lular bacteria and is independent of TLR4.
LPS O-antigen polysaccharide also contributes to Fran-
cisella pathogenicity by modulation of complement C3
activity. C3 deposition occurs on the surface of all virulent
Francisella strains, but surface located C3b is converted to
C3bi [74]. While C3b leads to cell lysis and opsonization,
C3bi is only opsonizing and greatly enhances phagocytic
uptake [43, 45, 75]. C4b and factor H deposition occurs
normally on the surface of bacteria, but the C5b-C9
membrane attack complex (MAC) does not form, resulting
in resistance to complement-mediated lysis [76]. Altered6 Journal of Pathogens
O-polysaccharide structures (as occurs in the LVS strain),
renders the bacteria sensitive to complement through the
C3b pathway and results in attenuation of virulence [74].
O-antigen from F. tularensis and LVS forms a capsular
polysaccharide around the organism [77]. Loss of this cap-
sule results in increased serum killing, reduced intracellular
replication and hyper cytotoxicity toward macrophages [77,
78]. Conversely, F. novicida does not produce an O-antigen
polysaccharide capsule, yet it is still resistant to complement-
mediated lysis suggesting that distinct mechanisms of com-
plement resistance may exist in this related strain [74, 77].
Passive transfer of serum raised against bacteria lacking the
O-antigen, or immunization of mice with such a strain,
does not protect mice from challenge by wild type bacteria,
indicating that the O-antigen is also important for the
development of humoral immunity [79, 80].
In addition to resisting the downstream eﬀects of
complement deposition, Francisella has also acquired mech-
anisms to resist human β-defensins (hBD) [81]. hBD-1
and hBD-2 show minimal to moderate bactericidal activity,
respectively, against LVS and F. novicida, but only at arti-
ﬁcially high concentrations. Conversely, hBD-3, which has
potent antimicrobial activity towards many microorganisms,
kills Francisella eﬀectively [82, 83]. hBD-1 is constitutively
expressed by lung type II epithelial cells while hBD-2 and
hBD-3 expression is inducible [84, 85]. Consequently, to
evade hBD-3, Francisella suppresses its expression in type
II cells [81]. The mechanism of this suppression and the
bacterial virulence factor(s) involved remain unknown.
Although Francisella has evolved a hypoinﬂammatory
cell surface, mammalian hosts have coevolved methods to
detect the organism through alternative mechanisms. To this
end, it has been known for some time that TLR2 activation
and MyD88-dependent and independent signaling as well as
induction of the inﬂammasome can result in eﬀective clear-
ance of Francisella in mouse models, and crosstalk between
these pathways is critical [62, 86–91]. TLR2 recognition of
Francisella lipoproteins likely occurs in the phagosome and
results in protection of mice from lethal infection [62, 87,
92, 93]. Cell based assays indicate that LVS decreases TLR2-
induced inﬂammation by activating phosphatidylinositol
3-kinase (PI3K) and upregulating MAPK phosphatase-1
(MKP-1), resulting in suppressed proinﬂammatory cytokine
production from infected macrophages [94]. Whether this
also occurs in airway epithelial cells has not yet been
determined.
Until recently, in fact, relatively little attention has been
given to the role of alveolar epithelial cells in Francisella
pathogenesis, but bacteria are able to invade these cells in
vitroandinvivo[95].ToadheretotypeIIcells,LVSexpresses
FsaP (F. tularensis surface associated protein), which pro-
motestightassociationtoepithelialcellsinvitroandmayalso
use type IV pili [96, 97] .S i m i l a rt om a c r o p h a g e s ,i n v a s i o n
into alveolar epithelial cells is dependent on a preformed
bacterial surface structure, as live and dead bacteria are
internalizedinamannerindistinguishablefromoneanother.
Invasion requires cells to be competent in cytoskeleton
rearrangement, as inhibiting microﬁlament and microtubule
activity abrogates internalization suggesting that it may
enter through endocytosis. Internalized bacteria initially
colocalize with the early endosomal marker EEA1, then
later with the lysosomal marker LAMP-1. Bacteria then
escape this compartment and replicate in the cytoplasm
[98]. Interestingly, type II pneumocytes are stimulated to
produce proinﬂammatory cytokines in vitro by F. tularensis,
and thus, it is unclear whether airway epithelial cells sense
and appropriately respond to invading bacteria [99].
Upon pulmonary challenge with Francisella, proinﬂam-
matory chemokine production by type II pneumocytes, as
well as induction of matrix metalloproteinase-9 (MMP-
9) and subsequent breakdown of the extracellular matrix,
recruits neutrophils to the sites of infection [99, 100]. How-
ever, recent evidence suggests that during transendothelial
migration, neutrophils acquire a depressed inﬂammatory
phenotype that prevents exogenous activation [101]. Artiﬁ-
cial depletion or recruitment of neutrophils during infection
has little impact on the outcome of disease, indicating that
bacteria are either resistant to neutrophil eﬀector function,
other cell types are able to control the infection, or both
[102]. Subsequent analysis has shown that LVS inhibits
NADPH oxidase assembly, supporting the hypothesis that
bacteria are resistant to neutrophil function [103, 104].
Multiple virulence genes are required for LVS to inhibit
oxidative burst in human neutrophils, including a number of
acid phosphatases as well as pyrimidine biosynthesis genes
[105–107].
4.2. Staphylococcus aureus. Staphylococcus aureus is a Gram-
positive, opportunistic human pathogen, a commensal of
the skin that colonizes an estimated 30% of the population
and is a leading cause of hospital acquired infection. More
recently, in addition to antibiotic resistant strains, more
invasive isolates have emerged due to numerous genes
acquired by this constantly evolving pathogen [108, 109].
Staphylococcal endocarditis, pneumonia, and sepsis now
pose signiﬁcant threats to both healthy and immune com-
promised individuals. These strains, known as community
associated methicillin resistant S. aureus (CA-MRSA), now
predominate inthehumanpopulation worldwideandareno
longer limited to nosocomial infections.
Innate immune recognition of S. aureus is largely ach-
ieved through TLR2-dependent recognition of lipoteichoic
acids, lipoproteins, and peptidoglycan, both from the cell
surface and on endosomes of antigen presenting cells
and type II epithelial cells [110–112]. In addition, mice
lacking MyD88 are more susceptible to S. aureus infection
suggesting that MyD88-dependent TLR2 signaling results
in productive induction of immune responses. However,
deletion of TLR2 did not completely abrogate induction
of cytokines in macrophages, while deletion of TLR4 had
no eﬀect. These results suggest that additional PRRs, other
than TLR2 and TLR4, detect S. aureus.R e c e n te v i d e n c e
points to a role for NLRs in recognizing S. aureus in
macrophages due to the action of pore-forming toxins [113].
Owing to this eﬃcient recognition of bacterial PAMPs,
virtually all humans carry antibodies that recognize and
opsonize S. aureus, and normal human serum promotesJournal of Pathogens 7
uptake by neutrophils. However, this does not always lead
tobacterialkilling.Instead,neutrophilsandotherphagocytic
cellscanbedestroyedbytheinvasivestrains[114,115].TLR2
activation leads to a proinﬂammatory response that recruits
neutrophils, monocytes, T cells, and B cells to the infection
site. In many cases, this response can be enough to clear the
infection. Additionally, S. aureus is susceptible to surfactant,
and opsonization of bacteria by SP-A can promote bacterial
clearance [116].
S. aureus encodes a number of adhesins that play
important roles in the pathogenesis of pneumonia. Invasion
of epithelial cells involves ﬁbronectin-binding protein and
adhesins that have been speciﬁcally linked with invasive
strains of Staphylococcus [117]. Invasion of these cells may
be at least in part responsible for the ability of the bacteria
to persistently colonize, as intracellular bacteria often evade
host immunity [118]. Following invasion of human type
II epithelial cells, there is little cell death in vitro [119].
In the intracellular environment, Staphylococci upregulate
genes involved in iron scavenging and virulence, includ-
ing several exotoxins, while simultaneously downregulating
surface expressed protein A and the virulence associated
transcription factor AgrA.
Invasion of S. aureus into nonphagocytic cells was
initially demonstrated in cultured mammary epithelial cells
[120, 121]. These experiments established that intracellular
bacteria could escape the endosome and induce apoptosis of
epithelial cells. More recently, S. aureus was shown to survive
inside activated neutrophils and induce pyroptosis following
escape from the phagolysosome [115]. Invasion of epithelial
cells can be accomplished through interactions between
bacterial ﬁbronectin binding protein and β1-integrins which
promote Src protein-tyrosine kinase signaling to internalize
the bacterium [122–124]. In addition, Staphylococcus adher-
ence to epithelial cells is enhanced following viral infection
which causes increased expression of host cell receptors such
as ICAM-1 and downregulation of TLR2. This likely allows
increased invasion and reduced NF-κB activation by the
airway epithelial cells.
S. aureus invasion of type II cells activates IFN-I. This
activation is caused by the recognition of the conserved,
multifunctional, secreted virulence factor protein A through
its repeated IgG-binding domains [125]. Activation of IFN-
I leads to IL-6 and TNF-α production but instead of
beneﬁtting the host, IFN-I is detrimental during S. aureus
infection. Mice lacking the IFN-I receptor, IFNAR, are more
resistant to Staphylococcal pneumonia, a phenotype that
correlates with a reduction in neutrophils and an increase
in dendritic cells recruited to the lungs. This eﬀect was
found to be independent of the adaptor TRIF and IFN-β,
while dependent on STAT-3. Thus, even though it is highly
stimulatory through PRRs, Staphylococcal protein A leads to
evasion of host immunity.
Protein A is a major virulence factor, secreted by all
pathogenic strains and required for the development of
pneumonia in murine models [126]. Protein A binds host
immunoglobulin with high aﬃnity, thereby preventing its
activation of Fc-receptor signaling. Protein A has long been
appreciated for its role in virulence due to this activity, as
well as interfering with the opsonization of Staphylococci,
blocking phagocytosis, and disabling complement ﬁxation
by the classical pathway. In addition, protein A binds with
high aﬃnity to TNF-R1, a receptor for the proinﬂammatory
cytokine TNF-α, on bronchial epithelial cells which leads to
therecruitmentof neutrophils tothe lungs[127].All of these
interactions are mediated through the repeated IgG binding
domains [128]. Thus the bacteria use a single protein to both
evade immunity and establish a replicative niche in the lungs
from inside and outside of host cells.
Extracellularbacteriaproducemanypore-formingtoxins
that speciﬁcally target leukocytes, some of which are unique
to more virulent strains of S. aureus, while others are
common to all of them [129–131]. Hemolysin is a well-
conservedtoxinthatplaysimportantrolesduringrespiratory
S. aureus infection. Hemolysin insertion into the plasma
membrane of target cells creates a pore that alters ion
gradients and membrane integrity, triggering cell death.
Upon forming a pore in the smooth muscle cells that drive
peristalsis, calcium release reduces contraction, allowing
S. aureus access to the epithelial layer. There, hemolysin
induces release of calcium from type II cells, leading to
upregulation of IL-6 and prostaglandin production and,
subsequently,inﬂammation[132,133].Highaﬃnitybinding
of α-hemolysin to type II epithelial cells is achieved through
protein-protein interactions with ADAM-10, which not only
leads to cell lysis, but also initiates signaling events that result
in disruption of focal adhesions in the epithelial layer [134].
Once the bacterium accesses the alveolar spaces, S. aureus
establishes a replicative niche, rapidly forming bacterial
colonies that appear resistant to host neutrophils and other
inﬂammatory cells [126]. Thus the activity of hemolysin
paradoxically triggers inﬂammation while promoting inva-
sion.
Other exotoxins are epidemiologically linked to invasive
CA-MRSA strains. For example, β-toxin of S. aureus binds
syndecan-1, is internalized, then renders the host cell more
vulnerable to other pathogen encoded toxins [135]. In addi-
tion, the toxin increases vascular permeability and edema in
the lung which exacerbates lung injury and inﬂammation.
Although not all pathogenic S. aureus strains carry β-
toxin, there appears to be a correlation between enhanced
capacity for respiratory infections and the presence of the
β-toxin gene [108]. CA-MRSA strains express an additional
virulencefactortermedPanton-Valentine Leukocidin (PVL),
a toxin that assembles into pore-forming octamers on the
surface of host cells. Association between PVL expression
and the pathogenesis of Staphylococcal pneumonia appears
evident in the human population, but a deﬁnitive role
in virulence in mouse and rabbit models of infection is
controversial. When PVL is overexpressed, it appears to
promote pneumonia in a mouse model [136]. However,
when expressed at endogenous levels, PVL is not required
for invasive Staphylococcal disease [137]. Nevertheless, PVL
possesses potent membrane lysing activity on human neu-
trophils [138, 139]. In addition to this well-characterized
activity, PVL also modulates signaling through TLR2 [140].
Puriﬁed PVL toxin is suﬃcient to cause TLR2- and CD14-
dependent inﬂammatory responses in the lungs following8 Journal of Pathogens
intranasal inoculation, suggesting multiple roles for TLR2 in
responding to S. aureus invasion of the lung [137].
4.3. Yersinia pestis. Similar to F. tularensis, Yersinia pestis is a
Gram-negative coccobacillus and is naturally transmitted to
mammalian hosts by an arthropod vector [141]. Transmis-
sion via ﬂeabite results in bubonic plague that can spread
from the lymph to the blood, where organisms can then
reach the lungs and cause secondary pneumonic plague.
Once in the lung, organisms can be spread from person to
person via aerosol droplets resulting in primary pneumonic
plague, an acute bronchopneumonia. Pneumonic plague
presents as a biphasic disease in that during the ﬁrst 24–
36 hours of infection little inﬂammation is observed. The
lung environment then abruptly turns proinﬂammatory,
accompanied by rapid bacterial growth and tissue necrosis
[142]. Pulmonary infection ultimately results in a patchy
bronchopneumoniacontainingnecroticlesionscomposedof
ﬁbrin, neutrophils, and bacterial colonies [143]. In humans,
symptoms include fever, headache, weakness, bloody spu-
tum, and dyspnea. If left untreated, the infection is nearly
always fatal.
Y. pestis has acquired mechanisms to modify its LPS
structure in response to temperature which prevents recog-
nition of the bacterium by TLR4. When grown at lower
temperatures (21–27◦C), Y. pestis expresses a mixture of
tri-acyl, tetra-acyl, penta-acyl, and hexa-acylated lipid A
structures which may be beneﬁcial for growth in this
environment [144, 145]. However, when grown at the
mammalian body temperature (37◦C), tri-acyl and tetra-
acyl lipid A structures predominate, with no detectable
hexa-acylation. Consequently, LPS isolated from bacteria
grown at 37◦C does not stimulate TLR4, and NF-κBi sn o t
activated in human inﬂammatory cells, thereby delaying
production of TNF-α and IL-8 [146–148]. LPS isolated
from bacteria grown at 37◦C also inhibits TLR4 activation.
Shown in mixing experiments, Y. pestis LPS from bacteria
grown at 37◦C can suppress TLR4 activation elicited from
normally proinﬂammatory LPS [149]. Similar results are
seen in dendritic cells, where it has also been shown that
tetra-acylated LPS inhibits cell signaling through TLR2
and TLR9 and inhibits upregulation of the Costimulatory
molecules MHC-II, CD40, and CD86 [150]. Together, the
data demonstrate that LPS modulates TLR signaling through
multiple mechanisms and is of centralimportance toY. pestis
virulence.
Yersinia pestis also uses a type III secretion system
(T3SS) to control inﬂammatory responses during infection
through the injection of Yersinia outer proteins (Yops) into
the host cell cytosol. Injection of Yops blocks phagocytic
uptake by neutrophils, macrophages, and dendritic cells and




to play multiple roles in vivo. Mutants that lack the T3SS
are avirulent in pneumonic plague models, where they fail to
evade early innate immune responses in the lung [154, 155].
Depletion of TNF-α but not IL-1β causes an increase in
sensitivity of mice to Y. pestis lacking YopH, but not wild
type bacteria, suggesting that YopH may impact the ability
of the host to induce NF-κB responses. Another type III
eﬀector protein, YopJ, has long been known to aﬀect NF-
κB responses in macrophages. Recently, YopJ was shown to
have similar activity when injected into bronchial epithelial
cells where it reduced NF-κB regulated gene expression,
suggesting that this virulence factor may help prevent
unwanted inﬂammatory responses during the early stages
of infection [156]. However, YopJ is relatively dispensable
for virulence during pneumonic plague, suggesting that
additional mechanisms for suppressing NF-κB regulated
genes in alveolar macrophages and epithelial cells dominate
during infection [157].
Eﬀective T3S into phagocytic and epithelial cells has
been shown to be dependent on the adhesive properties
conferred by membrane proteins. Three proteins have been
identiﬁed in Y. pestis that contribute this activity: Ail, Pla,
andPsa.Ail(attachment-invasionlocus)mediatesbindingto
ﬁbronectin, a component of the extracellular matrix [158].
Pla (plasminogen activator) has proteolytic and adhesive
properties that also mediate binding to the extracellular
matrix and perhaps other receptors on alveolar macrophages
and dendritic cells [159–161]. Psa (pH 6 antigen) ﬁmbriae
bind to phosphatidylcholine, a component of cell mem-
branes and surfactant, and to β1-linked, galactosyl-linked
residues in glycosphingolipids [162, 163]. Psa appears to be
more important for binding alveolar epithelial cells than
to macrophages indicating that it may play a central role
in penetration of the airway epithelium [164]. However,
Psa is relatively dispensable for virulence during pneumonic
plague, whereas Pla and Ail are essential [164]. Loss of all
of these factors markedly reduces Yop-induced cytotoxicity
towards target cells and attenuates virulence [165–168].
Y. pestis has a rough LPS structure and does not
synthesize an O-antigen domain. Instead, bacteria utilize the
multifunctional proteins mentioned above to resist killing
by host antimicrobial molecules. Ail is highly expressed
on the bacterial membrane at 26◦Ca n d3 7 ◦C and confers
resistance to complement-mediated killing by serum derived
from humans, rats, rabbits, sheep, goats, and guinea pigs
but is dispensable for resistance to mouse serum [169].
Accordingly, strains lacking ail are highly attenuated in a rat
model of pneumonic plague while in mice, ail mutants result
in an increase in mean time to death, perhaps indicating
a role for adhesion and internalization in vivo [170]. In
addition, antimicrobial peptides such as cathelicidin and
β-defensin have antimicrobial activity against attenuated
strains of Y. pestis in vitro, and expression of the surface
located virulence factors Pla and CaF1 (Capsular protein
F1) inﬂuence susceptibility to these peptides [171]. Pla is
a serine protease with broad spectrum activity that plays
an essential role in the development of pneumonic plague.
Pla-catalyzed cleavage of cationic antimicrobial peptides
provides a mechanism whereby Y. pestis can cleave and
inactivate CAMPs [171]. Paradoxically, expression of CaF1,
which forms antiphagocytic pili on the Y. pestis cell surface
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Figure 1: Disruption of airway defenses by Francisella, Staphylococcus, and Yersinia. Summary of host pathogen interactions used by these
bacteria to modulate innate immune responses and invade the airway.
likely through steric interference or alteration of substrate
speciﬁcity. Pla may also directly mediate serum resistance
due to its proteolytic activity on C3 [160].
Yersinia species are thought to be capable of invading
epithelial cells through interactions between one or more
adhesins and host cell β1 integrins [172]. At least three path-
ways of invasion have been suggested based on interactions
between enteropathogenic Yersiniae and epithelial cells, the
most eﬃcient of which, mediated by the protein Invasin,
is not likely not to occur in Y. pestis because this gene is
not expressed [173]. Nevertheless, invasion of the bronchial
or type II alveolar epithelial cells is an attractive model by
which Y. pestis would successfully penetrate the epithelial
barrier without causing inﬂammation at early stages of
infection. Alternative mechanisms for how bacteria invade
the epithelium involve the action of one or more toxins
produced by extracellular bacteria. In support of this model,
Pla is required for Y. pestis to invade the lung parenchyma,
suggesting that it may have a role in enhancing penetration
of the alveolar epithelium [168].
Even under conditions that support high level, simulta-
neous expression of virulence factors that suppress phago-
cytosis and contribute to the extracellular lifecycle of Y.
pestis, a small percentage of bacteria are engulfed by phago-
cytes in vitro [174]. Intracellular bacteria are equipped to
resist antimicrobial activity and proliferate even in IFN-γ
activated macrophages [175, 176]. Once phagocytosed by
macrophages, bacteria prevent the acidiﬁcation of vacuoles
and begin replicating independent of the T3SS [177, 178].
Replication in activated macrophages requires the protein
RipA which directly reduces NO levels without modulat-
ing iNOS expression [175]. Intracellular survival is also10 Journal of Pathogens
dependent on phoPQ (a two-component signal transduction
system that responds to low [Mg+2]), ugd, pmrK (predicted
phagosomal antimicrobial peptide resistance genes), and
mgtC (a low-Mg2+ induced gene) which are important for
theearlyintracellularsurvivalofY. pestis [179–181].Inaddi-
tion, antibody opsonization of Y. pestis promotes phagocytic
uptake, but the bacteria are not killed by macrophages and
bacterial clearance by opsonizing antibodies requires neu-
trophils [182–184]. Together, the data suggest that survival
in alveolar macrophages and perhaps also epithelial cells
lining the airway may be an important virulence mechanism
for invasive strategies utilized during pneumonic plague
[164].
In addition to inhibiting bacteria from being inter-
nalized, T3S by extracellular bacteria also inhibits ROS
production in phagocytic cells which is required to eliminate
intracellular bacteria [153]. Neutrophils are resistant to Yop-
inducedapoptosisandinhibitionofROSproductionappears
to prevent cells from undergoing phagocytosis-induced cell
death (PICD), a mechanism used by neutrophils to contain
infectionandresolveinﬂammation[185,186].Thus,thedata
support a model whereby T3S blocking antibodies prevent
Yopinjectionintoneutrophils,allowingROSproductionand
subsequent killing of intra- and extracellular bacteria.
5. Conclusions
The mammalian lower respiratory tract is largely protected
by the functions of airway epithelial cells. These cells
are sentinels, orchestrating recruitment, activation and de-
activation of inﬂammatory cells when microbes attempt to
invade the lung. Through the continuous production of
mucin and surfactant loaded with antimicrobial molecules,
potentiallyharmfulbacteriaaretrappedandcleared.Ifbacte-
ria can avoid or resist these normally protective mechanisms,
they need only to destroy or cross these cells to establish
a replicative niche before an onslaught of inﬂammatory
cells arrives. Yersinia, Francisella, and Staphylococcus, three
bacterial pathogens with the capability to cause lower
respiratory tract infection and acute pneumonia, possess
multiple mechanisms for penetrating the epithelium and
evading innate immunity, many of which exploit these
defense mechanisms to promote virulence (Figure 1). In
common between these and other bacterial pneumonias is
the use of cell surface structures that evade recognition and
resist the antimicrobial defenses of the airway epithelium.
Bacterial pathogens have enormous capacity for continuous
and rapid evolution allowing organisms to adapt in order to
further tip the balance of host-pathogen interactions in favor
of invasion across the epithelium, replication, and disease.
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